文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

抗菌药物耐药性领导联盟:科学进展与未来方向

The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本文概述抗菌药物耐药性领导联盟(ARLG)在患者诊疗、临床试验设计和导师培养方面的贡献,并展望未来重点。ARLG聚焦革兰阳性感染、革兰阴性感染和诊断三大领域,开发了结局期望排序(DOOR)方法和MASTERMIND主方案设计,并启动了噬菌体治疗囊性纤维化患者铜绿假单胞菌慢性定植的随机双盲安慰剂对照试验。

要点

  • ARLG聚焦革兰阳性感染、革兰阴性感染和诊断三大研究领域。
  • DOOR采用全局结局的序数测量同时评估获益与危害,已用于观察性研究和干预性试验分析。
  • MASTERMIND设计允许在单一研究中同时测试多个诊断平台。

核心结论

  • ARLG在患者诊疗、临床试验设计和导师培养方面做出重要贡献,并规划了未来优先方向。

研究设计与样本

  • 本文为ARLG贡献与未来方向的概述性文章。

主要发现

  • ARLG研究议程聚焦革兰阳性感染、革兰阴性感染和诊断三大关键领域。
  • DOOR最初应用于观察性研究,用于确定万古霉素治疗耐甲氧西林金黄色葡萄球菌菌血症的最佳剂量,以及比较头孢他啶-阿维巴坦与黏菌素治疗碳青霉烯类耐药肠杆菌目感染的疗效。
  • DOOR正成功应用于干预性试验分析,并与美国食品药品监督管理局(FDA)合作用于注册试验。
  • ARLG开发了MASTERMIND主方案,允许在单一研究中同时测试多个诊断平台,将用于比较鉴定氟喹诺酮耐药淋病奈瑟菌的分子检测(MASTER GC)和比较血流感染快速诊断检测。
  • ARLG启动了一项首创的随机双盲安慰剂对照试验,在铜绿假单胞菌慢性定植的囊性纤维化参与者中评估噬菌体疗法的药代动力学和抗菌活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chambers HF, Cross HR, Souli M, et al. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clin Infect Dis. 2023. PMID: 37843121. doi:10.1093/cid/ciad475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。